Skip to main content
OXFORD BIODYNAMICS PLC logo

OXFORD BIODYNAMICS PLC — Investor Relations & Filings

Ticker · OBD ISIN · GB00BD5H8572 LEI · 2138005Y1TK258O5U928 IL Professional, scientific and technical activities
Open in API
Filings indexed 416 across all filing types
Latest filing 2025-11-11 Major Shareholding Noti…
Country GB United Kingdom
Listing IL OBD

About OXFORD BIODYNAMICS PLC

https://www.oxfordbiodynamics.com/

Oxford BioDynamics PLC is a global biotechnology company advancing personalized healthcare by developing and commercializing precision medicine tests. The company's proprietary EpiSwitch® platform utilizes 3D genomics and epigenetic biomarkers to create diagnostic solutions for life-changing diseases, with a focus on oncology. Its portfolio of clinical tests includes the EpiSwitch® PSE, a blood test that assesses the likelihood of prostate cancer with high accuracy to help reduce unnecessary biopsies, and the EpiSwitch® CiRT, a test designed to predict a patient's therapeutic response to Immune Checkpoint Inhibitor cancer therapies. The platform enables the translation of 3D genome regulation into clinical applications for precision medicine at scale.

Recent filings

Filing Released Lang Actions
Holding(s) in Company
Major Shareholding Notification Classification · 100% confidence The document is a 'TR-1: Standard form for notification of major holdings', which is a regulatory requirement for shareholders to disclose when their voting rights in a company cross specific thresholds. This is a classic 'Major Shareholding Notification' filing, which corresponds to the code 'MRQ'.
2025-11-11 English
Holding(s) in Company
Major Shareholding Notification Classification · 100% confidence The document is a 'TR-1: Standard form for notification of major holdings', which is a regulatory requirement for shareholders to disclose when their voting rights in a company cross certain thresholds. This is a classic 'Major Shareholding Notification' filing, which corresponds to the code 'MRQ'.
2025-11-11 English
PDMR Dealing / Grant of Share Options
Director's Dealing Classification · 100% confidence The document is an official announcement from Oxford BioDynamics PLC regarding the grant of share options to directors and persons discharging managerial responsibilities (PDMRs). It includes detailed tables of the transactions, which are required disclosures under the UK Market Abuse Regulation. This falls squarely under the definition of 'Director's Dealing' (DIRS), as it reports personal share-related transactions by company executives.
2025-11-10 English
Result of General Meeting/PDMR Dealings
AGM Information Classification · 100% confidence The document is a regulatory announcement from Oxford BioDynamics PLC regarding the results of a General Meeting and subsequent Director/PDMR dealings (insider trades). While it mentions the General Meeting, the primary focus and the bulk of the content are the detailed disclosures of share purchases by directors and PDMRs following a fundraising event. This aligns perfectly with the 'Director's Dealing' (DIRS) category, which covers reports of personal share transactions by company directors and executives.
2025-11-07 English
Fundraising, Posting of Circular & Notice of GM
Share Issue/Capital Change Classification · 100% confidence The document is an announcement from Oxford BioDynamics PLC regarding a capital raise (placing and subscriptions) of £7 million. It details the terms of the fundraising, the necessity of shareholder approval at an upcoming General Meeting, and provides background information on the company's business strategy and financial position. This fits the definition of a Capital/Financing Update (CAP) as it describes fundraising activities and changes to the company's capital structure.
2025-10-22 English
OBD in New Report on NHS Prostate Cancer Screening
Regulatory Filings Classification · 100% confidence The document is a press release distributed via the RNS (Reach) service. It announces that Oxford BioDynamics PLC is noting the publication of a third-party report by 'Prostate Cancer Research' regarding NHS screening. The document does not constitute a financial report, audit, or regulatory filing of the company itself, but rather a corporate announcement regarding external news and its impact on the company's product. As it does not fit into specific categories like 10-K, IR, or ER, it falls under the general regulatory/corporate announcement category.
2025-10-14 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.